FOLH1 and neoplasm: By selectively targeting PSMA-expressing tumor cells, radioligand therapies (RLT) like [177Lu]Lu-PSMA therapy have demonstrated promising results such as delayed disease progression and improved disease outcomes in patients with mCRPC.